Tofacitinib in Polymyalgia Rheumatica (EAST PMR Study) An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with PMR. https://t.co/XQL7bfkkho https://t.co/HJ2aSIG0rn